Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Decreases By 72.8%

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 449,200 shares, a decline of 72.8% from the September 15th total of 1,650,000 shares. Currently, 1.6% of the shares of the stock are sold short. Based on an average trading volume of 4,780,000 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a research report on Thursday, October 3rd.

BriaCell Therapeutics Stock Performance

Shares of BriaCell Therapeutics stock opened at $1.01 on Friday. BriaCell Therapeutics has a one year low of $0.46 and a one year high of $5.97. The company has a market cap of $18.47 million, a price-to-earnings ratio of -0.81 and a beta of 1.34. The business’s 50 day moving average price is $0.73 and its 200 day moving average price is $1.34.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. K.J. Harrison & Partners Inc raised its holdings in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 7.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,044 shares of the company’s stock after purchasing an additional 6,329 shares during the quarter. K.J. Harrison & Partners Inc owned 0.54% of BriaCell Therapeutics worth $249,000 as of its most recent SEC filing. 15.42% of the stock is owned by hedge funds and other institutional investors.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.